# A Study of the Safety, Tolerability and Preliminary Efficacy of B2065 in Patients With Acute Ischemic Stroke.

> **NCT07371624** · PHASE1,PHASE2 · RECRUITING · sponsor: **Tasly Pharmaceutical Group Co., Ltd** · enrollment: 54 (estimated)

## Conditions studied

- Acute Ischemic Stroke

## Interventions

- **DRUG:** B2065
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07371624
- **Lead sponsor:** Tasly Pharmaceutical Group Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-31
- **Primary completion:** 2027-12
- **Final completion:** 2027-12
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2026-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07371624

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07371624, "A Study of the Safety, Tolerability and Preliminary Efficacy of B2065 in Patients With Acute Ischemic Stroke.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07371624. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*